Technology ID

Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers

Lead Inventor
Shah, Nirali (NCI)
Orentas, Rimas (NCI)
Pastan, Ira (NCI)
Mackall, Crystal (NCI)
Dimitrov, Dimiter (NCI)
Therapeutic Areas
Development Stages
Clinical Phase I
Lead IC

Chimeric antigen receptors (CARs) are hybrid proteins consisting of an antibody binding fragment fused to protein signaling domains that cause T-cells which express the CAR to become cytotoxic.  Once activated, these cytotoxic T-cells can selectively eliminate the cells which they recognize via the antibody binding fragment of the CAR.  Thus, by engineering a T-cell to express a CAR that is specific for a certain cell surface protein, it is possible to selectively target those cells for destruction.  This promising new therapeutic approach is known as adoptive cell therapy.
CD22 is a cell surface protein expressed on a large number of B-cell lineage hematological cancers, such as leukemia and lymphoma.  Several promising therapies are being developed which target CD22, including therapeutic antibodies and immunotoxins.  This technology concerns the use of a high affinity antibody binding fragment to CD22 (known as m971), as the targeting moiety of a CAR. The resulting CAR can be used in adoptive cell therapy treatment for cancer.

Competitive Advantages:

  • High affinity of the m971 antibody binding fragment increases the likelihood of successful targeting
  • Targeted therapy decreases non-specific killing of healthy, essential cells, potentially resulting in fewer non-specific side-effects and healthier patients
  • Hematological cancers are susceptible to cytotoxic T-cells for treating because they are present in the bloodstream 
  • Expression of CD22 only on mature cells avoids stem cell elimination during treatment


Commercial Applications:

  • Treatment of diseases associated with increased or preferential expression of CD22
  • Hematological cancers such as chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL) and pediatric acute lymphoblastic leukemia (ALL)


Licensing Contact: